Hemodialysis.-Induced Hypotension Therapy for End Stage Kidney Disease
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
Bradykinin is a potent vasodilator that is formed by the activation of the kallikrein-kinin
system. We and others have shown that bradykinin increased during hemodialysis; however, the
role of bradykinin in dialysis-induced hypotension (DIH) has not been evaluated. Preliminary
results from a pilot clinical trial showed that bradykinin B2 receptor blockade with
icatibant prevents excessive blood pressure during hemodialysis. Thus, in this study, we will
test the overarching hypothesis that blockade plasma kallikrein with lanadelumab would
ameliorate the reduction of blood pressure during hemodialysis in patients who are prone to
DIH. For this purpose, we will conduct a parallel arm, double-blind placebo-controlled trial,
using lanadelumab to evaluate the occurrence of